文献速递技术与安全MR

钆匹醇的发现:合理药物设计的一个范例?

The Discovery of Gadopiclenol: An Example of Rational Drug Design?
PubMed 文献 · Invest Radiol · 2025-12-01

本文回顾钆匹醇(gadopiclenol)的研发历程,阐述基于理化性质、药代动力学与毒性等多参数分子设计如何获得高弛豫率、高稳定性的非特异性磁共振对比剂。文中描述从原型P03277V1经异构化获得钆匹醇,并指出其临床定位由提高信号强度转向半剂量使用以减少钆暴露,目前以0.05 mmol/kg获批用于临床。

要点

  • 钆匹醇为宏环非离子型钆对比剂,内球含2个水分子,经合理设计获得高弛豫率与动力学稳定性。
  • 临床定位由提高信号强度转向半剂量(0.05 mmol/kg)使用,以减少钆注射及相关风险。
  • 是否可用0.1 mmol/kg剂量以增强临床诊断并改善患者管理,原文表示尚待观察。

核心结论

  • 钆匹醇的合理设计体现了药物化学中的基于性质的药物设计概念,也说明诊断药物设计的复杂性与治疗药物相当,且候选药物的医学定位可在临床开发过程中演变。

研究设计与样本

  • 本文为综述性文章,回顾钆匹醇的研发历程与分子设计策略,未报告系统检索范围与纳入文献数量。

诊断标准与关键数值

  • 钆匹醇的分子设计特征包括:基于PCTA骨架的宏环非离子结构且内球含2个水分子;在钆周围引入位阻约束以增强稳定性并减少内源性离子所致的弛豫淬灭;钆位于络合物中心使旋转扩散减慢;引入3条亲水性氨基多元醇侧臂以确保水溶性、减少与内源性蛋白结合并提高产品安全性。
  • 由原型P03277V1经异构化过程获得钆匹醇,后者表现出优异的动力学稳定性。
  • 钆匹醇目前获批临床使用的剂量为0.05 mmol/kg,以减少患者钆暴露。

局限性

  • 原文指出,0.1 mmol/kg剂量能否用于增强临床诊断并改善患者管理尚待观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Gadopiclenol was initially developed as a high-relaxivity, nonspecific magnetic resonance imaging contrast agent to enhance image quality and thereby improve diagnostics. This design required a highly demanding Drug Target Profile, addressing not only relaxivity but also factors such as physicochemical properties of the injectable solution (viscosity, osmolality, heat sterilization compatibility), pharmacokinetics and toxicity, particularly related to the stability of the complex. These considerations led to a multiparametric molecular design based on a gadolinium complex characterized by the following features: (1) a macrocyclic, nonionic structure based on the PCTA framework with 2 water molecules in the inner sphere; (2) the introduction of steric constraints around the gadolinium to enhance stability and reduce relaxivity quenching by endogenous ions; (3) slowed rotational diffusion due to gadolinium's position at the center of the complex; and (4) the incorporation of 3 hydrophilic amino polyol pendant arms to ensure aqueous solubility, reduce binding with endogenous proteins, and enhance product safety.This rational design led to the creation of a first prototype, P03277V1. However, the occurrence of nephrogenic systemic fibrosis necessitated modifications to the Drug Target Profile, aimed at improving the complex's stability and reducing production costs. This was achieved through the discovery of an isomerization process for P03277V1, resulting in gadopiclenol, which demonstrated excellent kinetic stability.The rational design of gadopiclenol thus exemplifies the concept of Property-Based Drug Design used in medicinal chemistry. It also highlights that the complexity of designing a diagnostic agent is comparable to that of a therapeutic agent. Furthermore, the case of gadopiclenol illustrates that the medical positioning of a drug candidate can evolve during clinical development. Gadopiclenol's medical positioning shifted from being a product with high relaxivity to improve signal strength, to one intended for use at a half dose to limit gadolinium injection and minimize risks to patients, such as nephrogenic systemic fibrosis or accumulation in specific areas of the brain. Currently, gadopiclenol is approved for clinical use at a dose of 0.05 mmol/kg to minimize gadolinium exposure to patients. Whether the 0.1 mmol/kg dose can be used to enhance clinical diagnostics and improve patient management in the future remains to be seen.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Port M. The Discovery of Gadopiclenol: An Example of Rational Drug Design? Invest Radiol. 2025. PMID: 40068194. doi:10.1097/RLI.0000000000001169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。